Literature DB >> 29520126

Optimum allocation for a dual-frame telephone survey.

Kirk M Wolter1, Xian Tao1, Robert Montgomery1, Philip J Smith2.   

Abstract

Careful design of a dual-frame random digit dial (RDD) telephone survey requires selecting from among many options that have varying impacts on cost, precision, and coverage in order to obtain the best possible implementation of the study goals. One such consideration is whether to screen cell-phone households in order to interview cell-phone only (CPO) households and exclude dual-user household, or to take all interviews obtained via the cell-phone sample. We present a framework in which to consider the tradeoffs between these two options and a method to select the optimal design. We derive and discuss the optimum allocation of sample size between the two sampling frames and explore the choice of optimum p, the mixing parameter for the dual-user domain. We illustrate our methods using the National Immunization Survey, sponsored by the Centers for Disease Control and Prevention.

Entities:  

Keywords:  Dual-frame surveys; National Immunization Survey; Optimum allocation; Sample design

Year:  2015        PMID: 29520126      PMCID: PMC5839168     

Source DB:  PubMed          Journal:  Surv Methodol        ISSN: 0714-0045            Impact factor:   0.378


  1 in total

1.  Statistical methodology of the National Immunization Survey, 1994-2002.

Authors:  Philip J Smith; David C Hoaglin; Michael P Battaglia; Meena Khare; Lawrence E Barker
Journal:  Vital Health Stat 2       Date:  2005-03
  1 in total
  2 in total

1.  Oversampling of Minority Populations Through Dual-Frame Surveys.

Authors:  Sixia Chen; Alexander Stubblefield; Julie A Stoner
Journal:  J Surv Stat Methodol       Date:  2020-01-11

2.  Moving towards a single-frame cell phone design in random digit dialing surveys: considerations from a French general population health survey.

Authors:  Noémie Soullier; Stéphane Legleye; Jean-Baptiste Richard
Journal:  BMC Med Res Methodol       Date:  2022-04-03       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.